Acute Myeloblastic Leukemia Type 1

Search Trials
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Withdrawn
Last Changed:
May 21, 2018
First Changed:
Apr 18, 2013
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
arsenic trioxidelaboratory biomarker analysis
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Status:
Completed
Last Changed:
Nov 17, 2017
First Changed:
Apr 15, 2013
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
pravastatin sodiumidarubicincytarabinelaboratory biomarker analysis
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Oct 29, 2018
First Changed:
Jul 22, 2013
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
lenalidomidemitoxantrone hydrochlorideetoposidecytarabine
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Status:
Active, not recruiting
Last Changed:
Jan 4, 2019
First Changed:
Feb 26, 2014
Disease(s):
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Intervention(s):
eltrombopag olamine
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Status:
Active, not recruiting
Last Changed:
Jan 4, 2018
First Changed:
Apr 24, 2013
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
azacitidinecytarabinemitoxantrone hydrochloridelaboratory biomarker analysis

Connect. Empower. Inspire.